Peer-reviewed journal articles featuring Fortrea oncologists published 2020-2024

Peer-reviewed journal articles featuring Fortrea oncologists published 2020-2024

San Francisco Bay Area biotech advances Phase I-II cancer immunotherapy trial with Fortrea

A San Francisco Bay Area biotech company approached Fortrea to manage a Phase I-II clinical trial evaluating a personalized, neoantigen-based vaccine.

Future directions in liquid biopsy technology

Recent technological advancements have dramatically improved the sensitivity of liquid biopsies, enabling earlier diagnosis, precise treatment selection and enhanced disease monitoring.

Guiding a biotech’s development of an immunotherapy cancer treatment with 'out-of-the-box' thinking

This case study delves into how Fortrea helped guide a sponsor's immunotherapy cancer treatment with out-of-the-box thinking.

Aligning core values to for a tripartite partnership and advance an oncology program

A partnership model matched the sponsor’s needs and enabled transparency in each interaction.

Our latest oncology publications

Our collaborative approach can result in co-authorship of peer-reviewed journal articles based on projects we’ve supported.

Accelerating Clinical Development through Design, Diversity & Digitalization in Oncology and Beyond

NICE technology appraisals of oncology treatments

Clinical Development in the Precision Medicine Era

The era of precision medicine is reshaping oncology trials, offering unprecedented opportunities to tailor treatments to individual genetic profiles. This transformation brings challenges in trial design and execution, and companies must adapt their clinical development strategies to stay ahead.

It is never too early to start a strategic plan for oncology product development in the APAC region

In oncology, a goal-oriented, holistic strategic plan is crucial, even in the earliest phases of product development. 

A Scientific Journey in the Midst of the Russia/Ukraine Conflict

Fortrea's efforts in continuing scientific research and clinical trials amidst the challenges posed by the Russia-Ukraine conflict.